Prioritize soft, cooked foods if you're experiencing nausea, especially in the first few weeks
As research progresses, personalized medicine approaches, novel drug formulations, and combination therapies will shape the future of obesity pharmacotherapy
Retatrutide is a triple GLP-1, GIP, and glucagon receptor agonist under clinical investigation for obesity, but it is not licensed by the MHRA or EMA in the UK
If you experience side effects from the combination, don't stop either medication on your own
BPC-157 is a great option for those seeking a natural, effective approach to healing and tissue repair
Association of HO-1 (GT)n promoter polymorphism and cardiovascular disease: a reanalysis of the literature